Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time

The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time: A Multicenter, Randomized, Parallel-Controlled Study

To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad treatment during the acute phase will increase the pain level, the recurrence rate of gout, and the inflammatory level of patients.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Gedetailleerde beschrijving

To confirm that initiating Dotinurad for uric acid uric acid lowering during the acute phase of gout is non-inferior to initiating it after the acute phase of gout has subsided, and to analyze whether initiating Dotinurad treatment during the acute phase will increase the pain level, the recurrence rate of gout, and the inflammatory level of patients. At the same time, to compare whether there are differences in the uric acid-lowering effects of initiating Dotinurad treatment at different times.And to evaluate the safety and tolerability of the treatment regimen.

Studietype

Ingrijpend

Inschrijving (Geschat)

142

Fase

  • Fase 4

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Male or female individuals aged 18-70 years old.
  • Meet the 2015 ACR/EULAR diagnostic criteria of gout.
  • With an onset of acute gout flares within 7 days.
  • With gout experiencing gout flares ≥2 times; or with gout experiencing gout flares 1 time and is younger than 40 years old; or with gout experiencing gout flares 1 time and has a serum uric acid level greater than 480 μmol/L and/or has co-morbidities (renal function impairment, hypertension,).
  • Provide a signed written informed consent form.

Exclusion Criteria:

  • Has secondary hyperuricemia.
  • Serum uric acid level < 360 μmol/L.
  • Used IL-1β inhibitors within 6 months before screening.
  • Used uric acid-lowering drugs within 1 month before screening.
  • Used anti-inflammatory drugs within 14 days before screening.
  • Comorbidities with nephrolithiasis or clinical urinary calculi
  • History of kidney transplantation or dialysis.
  • Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m².
  • AST or ALT > 2 times the upper limit of normal.
  • Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg during the screening period.
  • White blood cell count < 3.5 × 10⁹/L, or platelet count < 100 × 10⁹/L, or hemoglobin < 90 g/L.
  • Currently in the treatment period of malignant tumors, or within 6 months after the end of the treatment period.
  • Congestive heart failure (New York Heart Association [NYHA] cardiac function classification II-IV), confirmed ischemic heart disease, peripheral artery disease and/or cerebrovascular disease (including patients who have recently undergone coronary artery bypass grafting or angioplasty).
  • Hypersensitivity to the study drugs or their excipients, or all of urine alkalinizer (potassium citrate/sodium citrate hydrate compound preparations).
  • Have active gastrointestinal ulcers/bleeding, or have had a recurrence of ulcers/bleeding in the past.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: treatment group
The treatment group will be administered dotinurad 2 mg/day, colchicine 1 mg/day, and etoricoxib 120 mg/day (for 1-3 days) or 60 mg/day(for 4-7 days) for a duration of 4 weeks.
The drug used in the treatment group (from week 1 to 4)and the control group (from week 3 to 4). This is the main intervention factor of the study.
The drugs used throughout the treatment and control groups. In this design, it is part of the background treatment or the standard treatment.
The drugs used by the treatment group and the control group in the first week. It is also part of the background treatment.
Experimenteel: Control group
The control group will be administered colchicine 1 mg/day, and etoricoxib 120 mg/day (for 1-3 days) or 60 mg/day(for 4-7 days) for 2 weeks. Then the control group will be administered dotinurad 2mg/day, colchicine 1 mg/day for 2 weeks.
The drug used in the treatment group (from week 1 to 4)and the control group (from week 3 to 4). This is the main intervention factor of the study.
The drugs used throughout the treatment and control groups. In this design, it is part of the background treatment or the standard treatment.
The drugs used by the treatment group and the control group in the first week. It is also part of the background treatment.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Compare the days to resolution from enrolment to the resolution of an acute gout flare between the two groups
Tijdsspanne: From enrollment to the end of treatment at 12 weeks
From enrollment to the end of treatment at 12 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Compare the main joint visual analogue scale (VAS) scores of the two groups on the 1, 3, 7 and 14 days.
Tijdsspanne: From enrollment to the end of treatment at 1,3,7,14days
The VAS scores range is from 1 to 10. The higher the score, the more severe the pain.
From enrollment to the end of treatment at 1,3,7,14days
Compare the proportions of gout flares at 28 days between two groups
Tijdsspanne: From enrollment to the end of treatment at 28 days
From enrollment to the end of treatment at 28 days
Compare the proportions of subjects whose serum uric acid (SUA) levels were ≤ 360 umol/L at 7, 14 and 28 days between two groups
Tijdsspanne: From enrollment to the end of treatment at 7, 14 and 28 days
From enrollment to the end of treatment at 7, 14 and 28 days
Compare the percentage reduction in SUA from the baseline at 7, 14 and 28 days between two groups
Tijdsspanne: From enrollment to the end of treatment at 7, 14 and 28 days
From enrollment to the end of treatment at 7, 14 and 28 days
Compare the C-reactive protein (CRP) levels of the two groups at 7 and 14 days
Tijdsspanne: From enrollment to the end of treatment at 7,14days
From enrollment to the end of treatment at 7,14days
Compare the erythrocyte sedimentation rate (ESR) levels of the two groups at 7 and 14 days
Tijdsspanne: From enrollment to the end of treatment at 7,14days
From enrollment to the end of treatment at 7,14days

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

30 juli 2026

Primaire voltooiing (Geschat)

30 juli 2027

Studie voltooiing (Geschat)

30 juli 2027

Studieregistratiedata

Eerst ingediend

14 september 2025

Eerst ingediend dat voldeed aan de QC-criteria

16 juni 2026

Eerst geplaatst (Werkelijk)

22 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

22 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

16 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren